Morse M A, Lyerly H K
Departments of Medicine and Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Curr Opin Mol Ther. 2000 Feb;2(1):20-8.
Dendritic cells play a central role in the presentation of antigen to naïve T-cells and the induction of primary immune responses. Preclinical studies have established that dendritic cells loaded with antigens ex vivo induce potent antitumor and antiviral immune responses in vitro and in vivo. This has lead to a proliferation of clinical trials testing their effectiveness in humans, particularly with advanced malignancies. The few reported studies suggest that clinically relevant immune responses may be induced against some types of malignancies. Many questions regarding the best type of dendritic cell, degree of maturity, choice of antigen, route and schedule of administration, targeting to lymphoid tissue and use of additional adjuvants will need to be answered in preclinical and clinical studies as the field of dendritic cell-based immunotherapy progresses.
树突状细胞在将抗原呈递给初始T细胞以及诱导初级免疫反应中发挥核心作用。临床前研究已证实，体外负载抗原的树突状细胞在体外和体内均可诱导强大的抗肿瘤和抗病毒免疫反应。这导致了大量临床试验的开展，以测试其在人体中的有效性，尤其是针对晚期恶性肿瘤。少数已报道的研究表明，针对某些类型的恶性肿瘤可能会诱导出具有临床相关性的免疫反应。随着基于树突状细胞的免疫治疗领域的发展，在临床前和临床研究中，许多关于最佳树突状细胞类型、成熟程度、抗原选择、给药途径和方案、靶向淋巴组织以及使用其他佐剂的问题都需要得到解答。
